Onconova Therapeutics, Inc. (NASDAQ:ONTX) is reporting second quarter financial results on Wednesday 12th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ONTX is expected to report 2Q20 loss of $ 0.03 per share from revenue of $ 0.17 million.
For the full year, analysts anticipate top line of $ 3.09 million, while looking forward to loss of $ 0.12 per share bottom line.
Previous Quarter Performance
Onconova Therapeutics, Inc. posted loss for the first quarter of $ 0.03 per share, from the revenue of $ 0.05 million. The quarterly revenues decreased 37.50 percent compared with the same quarter last year. Wall street analysts are predicting, ONTX to report 1Q20 loss of $ 0.05 per share from revenue of $ 0.15 million. The bottom line results beat street analysts by $ 0.02 or 40.00 percent, at the same time, top line results fell short of analysts by $ 0.1 million or 66.67 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Onconova Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of ONTX was $ 1.10, representing a 1,000.00 % increase from the 52 week low of $ 0.10 and a 61.27 % decrease over the 52 week high of $ 2.84.
The company has a market capital of $ 191.59 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ONTX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Onconova Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.onconova.com
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.
